Blog

Yan Leyfman

Apr 18, 2025, 10:41

Yan Leyfman: Promising news in Parkinson’s research – results from a phase I clinical trial

Yan Leyfman, Co-founder and executive director of MedNews Week, shared a LinkedIn post about recent article V. Tabar and colleagues authored:

“Promising news in Parkinson’s research!

Researchers at Memorial Sloan Kettering Cancer Center report results from a phase I clinical trial (NCT04802733) using bemdaneprocel, an off-the-shelf dopaminergic progenitor cell therapy derived from human embryonic stem cells.

Key highlights:

12 patients received cell grafts into the putamen (low-dose vs high-dose cohorts)
No adverse events linked to the therapy
Increased 18F-DOPA PET uptake at 18 months
High-dose group saw an average 23-point improvement in MDS-UPDRS Part III OFF scores
No graft-induced dyskinesias

These findings show encouraging safety and early efficacy signals, paving the way for larger trials.”

Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease

Authors: V. Tabar et al.

Parkinson's research

A. Fasano A. Lampron A. M. Lozano bemdaneprocel C. Brennan C. Henchcliffe cancer D. Eidelberg H. Sarva K. K. H. Yu L. Studer M. Tomishima Memorial Sloan Kettering Cancer Center N. Abid OncoDaily Oncology Parkinson's research S. Irion S. K. Kalia S. Peng V. Tabar W. Stemple Y. Ma Yan Leyfman

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial